CLAIMS

What is claimed is:

1. A particle comprising at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent, wherein the particle has greater than about 60% therapeutic biologic by weight.

2. The particle of claim 1, wherein the hyaluronan degrading agent is hyaluronidase.

3. The particle of claim 2, wherein the hyaluronidase is a soluble neutral-active hyaluronidase.

4. The particle of claim 2, wherein the hyaluronidase is a mammalian hyaluronidase.

5. The particle of claim 4, wherein the mammalian hyaluronidase is a human hyaluronidase.

6. The particle of claim 5, wherein the human hyaluronidase is a recombinant human hyaluronidase (rHuPH20).

7. The particle of any one of the preceding claims, wherein the hyaluronan degrading agent in the particle is less than about 1% by weight.

8. The particle of any one of the preceding claims, wherein the particle has less than about 10% aggregation of the therapeutic biologic.

9. The particle of any one of the preceding claims, wherein the particle has a circularity of about 0.8 to about 1.00.

10. The particle of any one of the preceding claims, wherein the particle further comprises a carbohydrate, a pH adjusting agent, a salt, a chelator, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a paraben, a bactericide, a fungicide, a preservative, or a combination thereof.

11. A pharmaceutically effective composition comprising:

a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic

biologic or a salt thereof, and a hyaluronan degrading agent, and wherein substantially all of the parties have greater than about 60% therapeutic biologic by weight.

12. The composition of claim 11, wherein the concentration of the hyaluronan degrading agent in the composition is less than about 20000 U/mL.

13. The composition of claim 11 or 12, wherein the hyaluronan degrading agent is hyaluronidase.

14. The composition of any one of claims 11-13, wherein substantially all of the particles have less than about 10% aggregation of the therapeutic biologic.

15. The composition of any one of claims 11-13 and 14, wherein substantially all of the particles have a circularity of about 0.80 to about 1.00.

16. The composition of any one of claims 11-13, 14 and 15, wherein substantially all of the particles have less than about 25% internal void spaces.

17. The composition of any one of claims 11-13, 14, 15 and 16, wherein substantially all of the particles further comprise a carbohydrate, a pH adjusting agent, a salt, a chelator, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a paraben, a bactericide, a fungicide, a preservative, or a combination thereof.

18. The composition of any one of claims 11-13, 14, 15, 16 and 17, wherein the liquid carrier is non-aqueous.

19. The composition of claim 18, wherein the non-aqueous liquid carrier is an organic solvent.

20. The composition of any one of claims 11-13, 14, 15, 16, 17, 18, and 19, wherein the composition further comprises a flocculation agent.

21. The composition of claim 20, wherein the concentration of the flocculation agent in the composition is less than about 50 mg/mL.

22. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising:

a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent, and wherein substantially all of the particles have greater than about 60% therapeutic biologic by weight.

23. The method of claim 22, wherein the hyaluronan degrading agent is hyaluronidase.

24. The method of claim 22 or 23, wherein the disease or condition is cancer, inflammatory disease or an immune disease.

25. The method of any one of claims 22, 23 and 24, wherein substantially all of the particles have less than about 10% aggregation of the therapeutic biologic.

26. The method of any one of claims 22, 23, 24 and 25, wherein substantially all of the particles further comprise a carbohydrate, a pH adjusting agent, a salt, a chelator, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a paraben, a bactericide, a fungicide, a preservative, or a combination thereof.

27. A method of administering a pharmaceutically effective composition comprising:

a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent, and wherein substantially all of the particulars have greater than about 60% therapeutic biologic by weight.

28. The method of claim 27, wherein the composition is administered by subcutaneous injection.

29. The method of claim 27 or 28, wherein the composition is administered by a syringe or portable drug delivery injection device.

30. A kit comprising: a syringe or portable drug delivery injection device; and a composition comprising:

a plurality of particles suspended in a pharmaceutically acceptable liquid carrier, wherein substantially all of the particles comprise at least one therapeutic biologic or a salt thereof, and a hyaluronan degrading agent, and wherein substantially all of the particles have greater than about 60% therapeutic biologic by weight.